NGM Biopharmaceuticals, Inc. EBITDA Margin 2019-2023 | NGM
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for NGM Biopharmaceuticals, Inc. (NGM) over the last 10 years. The current EBITDA margin for NGM Biopharmaceuticals, Inc. as of December 31, 2023 is .
| EBITDA Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM EBITDA | EBITDA Margin |
| 2023-12-31 | $0.00B | $-0.16B | -3875.00% |
| 2023-09-30 | $0.02B | $-0.16B | -745.45% |
| 2023-06-30 | $0.03B | $-0.18B | -620.69% |
| 2023-03-31 | $0.04B | $-0.18B | -508.33% |
| 2022-12-31 | $0.06B | $-0.16B | -296.36% |
| 2022-09-30 | $0.06B | $-0.15B | -256.90% |
| 2022-06-30 | $0.07B | $-0.13B | -184.06% |
| 2022-03-31 | $0.08B | $-0.12B | -148.72% |
| 2021-12-31 | $0.08B | $-0.11B | -140.51% |
| 2021-09-30 | $0.08B | $-0.11B | -143.59% |
| 2021-06-30 | $0.08B | $-0.11B | -139.02% |
| 2021-03-31 | $0.09B | $-0.10B | -122.35% |
| 2020-12-31 | $0.09B | $-0.10B | -111.49% |
| 2020-09-30 | $0.10B | $-0.09B | -88.78% |
| 2020-06-30 | $0.10B | $-0.07B | -72.16% |
| 2020-03-31 | $0.10B | $-0.05B | -52.94% |
| 2019-12-31 | $0.10B | $-0.04B | -41.35% |
| 2019-09-30 | $0.12B | $-0.01B | -10.00% |
| 2019-06-30 | $0.12B | $-0.01B | -6.72% |
| 2019-03-31 | $0.12B | $-0.00B | -2.59% |
| 2018-12-31 | $0.11B | $0.00B | 1.83% |
